We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DXPE:NASDAQDXP Enterprises, Inc. Analysis

Data as of 2026-03-30 - not real-time

$135.29

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

DXP Enterprises is trading at $135.29, just below its 20‑day SMA of $135.78 but comfortably above the 200‑day SMA of $115.76, indicating a short‑term pull‑back within a longer‑term uptrend. Technicals show a bullish MACD histogram (+0.17) and an RSI of 47.9, suggesting neutral momentum with a slight upside bias, while volume is on the rise and the stock sits above the $125.23 support level with $147.30 as the next resistance. Fundamentals reveal a 12% revenue growth rate, a solid ROE of 19.3% and a forward PE of 18.66, which is well below the industry average PE of 27.96, yet the balance sheet is strained by a debt‑to‑equity ratio of 185% and modest free cash flow generation. The 30‑day volatility of 45% and a beta near 1.4 underscore heightened market sensitivity, amplified by recent macro‑economic headwinds from Middle‑East tensions that have pressured industrial stocks despite the company’s strong earnings beat.
Recent analyst commentary includes a Zacks Rank 1 “Strong Buy” upgrade, reflecting confidence in earnings momentum, but the broader sentiment remains cautious due to leverage and cash‑flow constraints. Overall, the stock presents a blend of growth and value attributes, with upside potential if the company can deleverage and sustain cash‑flow conversion, while short‑term price action may be volatile amid macro uncertainty.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Bullish MACD histogram with increasing volume
  • Price holding above key support at $125.23
  • Technical positioning near 20‑day SMA

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • 12% revenue growth and forward PE discount to peers
  • High debt‑to‑equity ratio limiting financial flexibility
  • Strong ROE but modest free cash flow conversion

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustained earnings momentum and solid ROE
  • Leverage and cash‑flow constraints that must be addressed
  • Potential upside if deleveraging improves balance‑sheet health

Key Metrics & Analysis

Financial Health

Revenue Growth12.00%
Profit Margin4.40%
P/E Ratio25.1
ROE19.25%
ROA7.36%
Debt/Equity185.48
P/B Ratio4.2
Op. Cash Flow$94.3M
Free Cash Flow$9.2M
Industry P/E28.0

Technical Analysis

TrendNeutral
RSI47.9
Support$125.23
Resistance$147.30
MA 20$135.78
MA 50$138.45
MA 200$115.76
MACDBullish
VolumeIncreasing
Fear & Greed Index67.93

Valuation

Target Price$139.50
Upside/Downside3.11%
GradeFair
TypeBlend

Risk Assessment

Beta1.44
Volatility44.99%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.